Skip to main content
ARS Home » Research » Publications at this Location » Publication #176529
Title: EARLY DEVELOPMENT OF ADENOVIRUS-VECTORED FMD VACCINE AND ANTIVIRAL

Author
item Grubman, Marvin
item Golde, William
item Rodriguez, Luis

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 8/1/2004
Publication Date: 10/10/2004
Citation: Grubman, M.J., Golde, W.T., Rodriguez, L.L. 2004. Early Development of Adenovirus-vectored FMD Vaccine and Antiviral. European Commission for the Control of Foot-and-Mouth Disease, Chania, Crete, Greece. P. 45.

Interpretive Summary:

Technical Abstract: Few effective intervention tools are available today to control FMD outbreaks. These include culling and slaughter of all animals in infected and neighboring contact premises and strict quarantines of the affected areas. These measures lead to massive accumulation of thousands of animal carcasses for disposal with the consequent disruption of commerce, tourism and transportation. Vaccination has been proposed as a tool to decrease susceptibility of animal populations in ring-vaccination schemes. Current vaccines have been designed and tested for protection at 3-4 weeks post-vaccination, creating a window of susceptibility in the vaccinated population. Previous experiments at PIADC have shown that recombinant Adenovirus-vectored FMD empty capsid (VLP) can protect swine and bovine against direct FMDV challenge by 7 days post vaccination. In addition Adenovirus-vectored porcine interferon can protect swine against FMD challenge in as little as 24 hours and for as long as 5 days post injection. The combination of vaccine and antiviral would close the window of susceptibility and could serve as emergency intervention tools to rapidly control FMD outbreaks. We are now taking these two products through early development utilizing a cell line approved for vaccine production and producing experimental vaccine lots under "Good Laboratory Practice" conditions in partnership with a private industry partner. With these products we will be evaluating novel approaches combining vaccination and antiviral therapy as intervention tools to rapidly control and minimize the impact of FMD outbreaks in the United States.